These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17151159)

  • 1. Effectiveness of switching antipsychotic medications.
    Essock SM; Covell NH; Davis SM; Stroup TS; Rosenheck RA; Lieberman JA
    Am J Psychiatry; 2006 Dec; 163(12):2090-5. PubMed ID: 17151159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Rosenheck RA; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
    Am J Psychiatry; 2006 Apr; 163(4):611-22. PubMed ID: 16585435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
    McEvoy JP; Lieberman JA; Stroup TS; Davis SM; Meltzer HY; Rosenheck RA; Swartz MS; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
    Am J Psychiatry; 2006 Apr; 163(4):600-10. PubMed ID: 16585434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What CATIE found: results from the schizophrenia trial.
    Swartz MS; Stroup TS; McEvoy JP; Davis SM; Rosenheck RA; Keefe RS; Hsiao JK; Lieberman JA
    Psychiatr Serv; 2008 May; 59(5):500-6. PubMed ID: 18451005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
    Swartz MS; Wagner HR; Swanson JW; Stroup TS; McEvoy JP; Reimherr F; Miller DD; McGee M; Khan A; Canive JM; Davis SM; Hsiao JK; Lieberman JA;
    Schizophr Res; 2008 Mar; 100(1-3):39-52. PubMed ID: 18191383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
    Swartz MS; Perkins DO; Stroup TS; Davis SM; Capuano G; Rosenheck RA; Reimherr F; McGee MF; Keefe RS; McEvoy JP; Hsiao JK; Lieberman JA;
    Am J Psychiatry; 2007 Mar; 164(3):428-36. PubMed ID: 17329467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
    Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
    Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
    N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
    Kinon BJ; Liu-Seifert H; Adams DH; Citrome L
    J Clin Psychopharmacol; 2006 Dec; 26(6):632-7. PubMed ID: 17110821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
    Vigen CL; Mack WJ; Keefe RS; Sano M; Sultzer DL; Stroup TS; Dagerman KS; Hsiao JK; Lebowitz BD; Lyketsos CG; Tariot PN; Zheng L; Schneider LS
    Am J Psychiatry; 2011 Aug; 168(8):831-9. PubMed ID: 21572163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
    McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD
    Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
    Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial.
    Rosenheck RA; Davis S; Covell N; Essock S; Swartz M; Stroup S; McEvoy J; Lieberman J
    Schizophr Res; 2009 Jan; 107(1):22-9. PubMed ID: 18993031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia.
    Takeuchi H; Fervaha G; Lee J; Agid O; Remington G
    Eur Neuropsychopharmacol; 2015 Mar; 25(3):295-302. PubMed ID: 25649680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
    J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.
    Heres S; Davis J; Maino K; Jetzinger E; Kissling W; Leucht S
    Am J Psychiatry; 2006 Feb; 163(2):185-94. PubMed ID: 16449469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain.
    Ciudad A; Haro JM; Alonso J; Bousoño M; Suárez D; Novick D; Gilaberte I
    Eur Psychiatry; 2008 Jan; 23(1):1-7. PubMed ID: 18023154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.